BioTime to Present at Global Bioproduction Summit

Co-CEO Dr. Michael West to Discuss Human Cell Manufacturing for
Regenerative Medicine

ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company
developing and commercializing products addressing degenerative
diseases, today announced that Co-Chief Executive Officer Michael D.
West, Ph.D., is delivering a presentation at the Global
Bioproduction Summit
, December 12-13, at the Hilton
San Diego Bayfront

Dr. West’s presentation, “Methodologies for Human Cell Manufacturing
from Pluripotent Stem Cells in the Application of Regenerative
Medicine,” will be delivered on Tuesday, December 13, at 9:20 a.m. PST
and will cover the following topics:

  • Where are we going wrong? – Contrasting the scale-up manufacturing of
    adult cells versus pluripotent cells, and analysing the advantages and
    disadvantages of both
  • A look into novel technologies for the reproducible manufacturing of 1st &
    2nd generation, highly-identified, purified products
    derived from pluripotent stem cells
  • Case Study – the unique phenotype of pluripotent-stem-cell-derived
    cells that could improve the process of tissue repair

A copy of Dr. West’s presentation will be made available on the BioTime website.

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what the
company believes to be the world’s premier collection of pluripotent
cell assets. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells that are capable of becoming any of the
cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient needs,
including various age-related degenerative diseases and degenerative
conditions for which there presently are no cures. Unlike
pharmaceuticals that require a molecular target, therapeutic strategies
based on the use of pluripotent cells are generally aimed at
regenerating or replacing affected cells and tissues, and therefore may
have broader applicability than pharmaceutical products.

In addition to the development of therapeutics, BioTime’s research and
other activities have resulted, over time, in the creation of other
subsidiaries that address other non-therapeutic market opportunities
such as cancer diagnostics, drug development and cell research products,
and mobile health software applications.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit
or connect with the company on Twitter,
and Google+.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:


Investor Contact:
EVC Group, Inc.
Matt Haines, 917-733-9297
Gotham Communications, LLC
Bill Douglass, 646-504-0890